Rigel says Pfizer returns asthma therapy rights – Reuters

Rigel says Pfizer returns asthma therapy rights
Reuters
May 6 (Reuters) – Rigel Pharmaceuticals Inc said Pfizer Inc has returned the rights to Rigel's inhaled asthma therapy, following the world's biggest drugmaker's decision to exit research and development in the allergy and respiratory therapeutic area.
Rigel Assumes Development Responsibility for Inhaled Asthma TherapyPR Newswire (press release)
Pfizer Hands Back Rigel DrugXconomy

all 12 news articles »

View full post on asthma – Google News

Rigel Assumes Development Responsibility for Inhaled Asthma Therapy – PR Newswire (press release)

Rigel Assumes Development Responsibility for Inhaled Asthma Therapy
PR Newswire (press release)
SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1

and more »

View full post on asthma – Google News